The Neos Therapeutics team is dedicated to creating high-quality products and partnering with pharmaceutical and consumer healthcare companies to address key medical needs. Neos Therapeutics research and development (RD) and manufacturing facilities are located in the Dallas/Fort Worth area. The Neos Therapeutics proprietary controlled release technology platforms for liquids and oral disintegrating tablets (ODTs) are used in both prescription and over-the-counter (OTC) drugs. These innovative delivery technologies address the needs of growing pediatric and geriatric patient populations, especially those with central nervous system disorders or an inability to swallow tablets and capsules. Neos licenses its delivery technology platform to pharmaceutical and OTC drug companies in addition to developing and marketing their own pipeline of CR liquids and CR ODTs. Neos proprietary formulation technology, Dynamic Time Release Suspension (DTRS), has been used to develop a newly approved Generic Tussionex extended release suspension product. The product was developed through collaboration with Cornerstone Therapeutics Inc. and Coating Place, Inc. , and will be exclusively manufactured by Neos Therapeutics. Neos Therapeutics Contract Manufacturing services include compound selection, analytical development, milling, blending, granulating, drying, compressing, coating, encapsulating, liquid mixing, emulsifying, packaging, stability storage, and QC testing. Their RD team and their Manufacturing facility fully support oral liquid, tablet, and capsule forms from development of initial concept to final packaging.